Paul Peter Tak is Chief Executive Officer, President and Director of Candel Therapeutics, Inc. (CADL). The company reported total compensation of $5,344,561 for fiscal year 2025.
| Salary | $743,592 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $3,916,028 |
| Non-equity incentive plan | $396,653 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $288,289 |
| Total | $5,344,561 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Candel Therapeutics, Inc. filed April 29, 2026, accession 0001193125-26-191506.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Paul Peter Tak this page | Chief Executive Officer, President and Director | $5,344,561 |
| Francesca Barone | Chief Scientific Officer | $1,561,536 |
| Charles Schoch | Chief Financial Officer, Treasurer and Secretary | $1,470,817 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Candel Therapeutics, Inc. compensation brief.
Paul Peter Tak's compensation sits inside Candel Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.